A G Babiker
Overview
Explore the profile of A G Babiker including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
27
Citations
659
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Zangari P, Palma P, Cotugno N, Rojo P, Tagarro A, Pepponi I, et al.
J Virus Erad
. 2018 Mar;
4(1):51-54.
PMID: 29568555
No abstract available.
2.
Stirrup O, Copas A, Phillips A, Gill M, Geskus R, Touloumi G, et al.
HIV Med
. 2017 Dec;
19(3):184-194.
PMID: 29230953
Objectives: To investigate factors that predict speed of recovery and long-term CD4 cell count in HIV-1 seroconverters initiating combination antiretroviral therapy (cART), and to quantify the influence of very early...
3.
Sharma S, Babiker A, Emery S, Gordin F, Lundgren J, Neaton J, et al.
HIV Med
. 2015 Feb;
16 Suppl 1:30-6.
PMID: 25711321
Objectives: The risks and benefits of initiating antiretroviral treatment (ART) at high CD4 cell counts have not been reliably quantified. The Strategic Timing of AntiRetroviral Treatment (START) study is a...
4.
Rabie H, Violari A, Duong T, Madhi S, Josipovic D, Innes S, et al.
Int J Tuberc Lung Dis
. 2011 Sep;
15(9):1194-200, i.
PMID: 21943845
Setting: Two centres in Soweto and Cape Town, South Africa. Objective: To assess the effects of timing of initiation of antiretroviral treatment (ART) and other factors on the risk of...
5.
Walker A, Ford D, Gilks C, Munderi P, Ssali F, Reid A, et al.
Lancet
. 2010 Mar;
375(9722):1278-86.
PMID: 20347483
Background: Co-trimoxazole prophylaxis can reduce mortality from untreated HIV infection in Africa; whether benefits occur alongside combination antiretroviral therapy (ART) is unclear. We estimated the effect of prophylaxis after ART...
6.
Munderi P, Walker A, Kityo C, Babiker A, Ssali F, Reid A, et al.
HIV Med
. 2010 Feb;
11(5):334-44.
PMID: 20136661
Background: Triple nucleoside reverse transcriptase inhibitor regimens have advantages as first-line antiretroviral therapy (ART), avoiding hepatotoxicity and interactions with anti-tuberculosis therapy, and sparing two drug classes for second-line ART. Concerns...
7.
Babiker A, Gilks C, Munderi P, Kabuye G, Kasirye R, Zalwango E, et al.
Lancet
. 2009 Dec;
375(9709):123-31.
PMID: 20004464
Background: HIV antiretroviral therapy (ART) is often managed without routine laboratory monitoring in Africa; however, the effect of this approach is unknown. This trial investigated whether routine toxicity and efficacy...
8.
Yeni P, Cooper D, Aboulker J, Babiker A, Carey D, Darbyshire J, et al.
Lancet
. 2006 Jul;
368(9532):287-98.
PMID: 16860698
Background: Antiretroviral therapy has greatly reduced HIV mortality and morbidity. However, the best sequence of regimens and implications of initial regimen for long-term therapeutic success are not well defined. Methods:...
9.
Dunn D, Green H, Loveday C, Rinehart A, Pillay D, Fisher M, et al.
J Acquir Immune Defic Syndr
. 2005 Mar;
38(5):553-9.
PMID: 15793365
Objectives: To assess the clinical utility of phenotypic resistance testing in addition to genotypic resistance testing among HIV-1-infected patients experiencing virologic failure and with limited therapeutic options. Design: Multicenter randomized...
10.
Touloumi G, Babiker A, Kenward M, Pocock S, Darbyshire J
Stat Med
. 2003 Oct;
22(20):3161-75.
PMID: 14518021
Several methods for the estimation and comparison of rates of change in longitudinal studies with staggered entry and informative drop-outs have been recently proposed. For multivariate normal linear models, REML...